23:15 , Oct 26, 2018 |  BioCentury  |  Product Development

R&D merry-go-round

An exodus of pharma R&D leaders to small biotechs and start-ups over the last year reflects a new phase in the ecosystem’s churn of talent. But it’s not all loss for the pharmas. The transition...
22:25 , Apr 13, 2018 |  BioCentury  |  Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
23:47 , Jul 5, 2017 |  BC Extra  |  Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
18:03 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Studies in mice suggest inhibiting HDAC2 could help treat peripheral nerve damage. In a mouse model of sciatic nerve injury, Schwann cell-specific knockout of HDAC2 increased axonal regrowth and sprouting compared with...
22:05 , Dec 9, 2016 |  BC Week In Review  |  Company News

Acetylon, Celgene deal

Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to...
00:07 , Dec 3, 2016 |  BC Extra  |  Company News

Celgene acquiring Acetylon after spinout of newco

Acetylon Pharmaceuticals Inc. (Boston, Mass.) said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston,...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Acetylon, Celgene deal

Celgene revealed in a regulatory filing that it did not exercise its option to acquire Acetylon. Celgene allowed the option to expire in May. It paid $100 million up front to acquire the option in...
07:00 , Aug 8, 2016 |  BC Extra  |  Company News

Celgene declines Acetylon option

Celgene Corp. (NASDAQ:CELG) revealed in a regulatory filing that it did not exercise its option to acquire Acetylon Pharmaceuticals Inc. (Boston, Mass.). Celgene allowed the option to expire in May. It paid $100 million up...